

Variant: NM_000051.4(ATM):c.5763-1050A>G

Version: 1.0

CA115927 [↗](#)

3021 (ClinVar) [↗](#)

Gene: ATM ([HGNC:472](#))

Condition: ATM-related cancer predisposition ([MONDO:0700270](#))

Inheritance Mode: Autosomal dominant inheritance

UUID: b257c0e3-7ed5-432e-b2bc-7441d8c0b1dc

Approved on: 2024-11-26

Published on: 2025-01-13

HGVS expressions

NM_000051.4:c.5763-1050A>G

NM_000051.4(ATM):c.5763-1050A>G
NC_000011.10:g.108309110A>G
CM000673.2:g.108309110A>G
NC_000011.9:g.108179837A>G
CM000673.1:g.108179837A>G
NC_000011.8:g.107685047A>G
NG_009830.1:g.91279A>G
NG_054724.1:g.165723T>C
ENST00000452508.7:c.5763-1050A>G
ENST00000713593.1:c.*5234-1050A>G
ENST00000278616.9:c.5763-1050A>G
ENST00000525056.2:n.182-1050A>G
ENST00000682286.1:n.520-1050A>G
ENST00000682302.1:n.181-1050A>G
ENST00000683174.1:n.7247-1050A>G
ENST00000683524.1:n.987-1050A>G
ENST00000684152.1:n.1477-1050A>G
ENST00000527805.6:c.*827-1050A>G
ENST00000675595.1:c.*827-1050A>G
ENST00000675843.1:c.5763-1050A>G
ENST00000278616.8:c.5763-1050A>G
ENST00000452508.6:c.5763-1050A>G
ENST00000524792.5:n.1978-1050A>G
ENST00000525729.5:c.641-39T>C
ENST00000529588.5:c.187-1050A>G
ENST00000532765.1:n.79+1040A>G
ENST00000533690.5:n.1167-1050A>G
NM_000051.3:c.5763-1050A>G
NM_001330368.1:c.641-39T>C
NM_001351110.1:c.*39-39T>C
NM_001351834.1:c.5763-1050A>G
NM_001330368.2:c.641-39T>C
NM_001351110.2:c.*39-39T>C
NM_001351834.2:c.5763-1050A>G

Pathogenic

Met criteria codes **3**

PVS1_Strong **PP1_Strong** **PM3_Very Strong**

Not Met criteria codes **2**

PP3 **PM2**

Evidence Links **0**

Expert Panel

[Hereditary Breast, Ovarian and Pancreatic Cancer VCEP](#)

Criteria Specification Information

[Criteria Specification:](#) *ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for ATM Version 1.3.0*

[Criteria Specification Approval History](#)







[Criteria Specifications for this VCEP](#)

Evidence submitted by expert panel

Hereditary Breast, Ovarian and Pancreatic Cancer VCEP

The c.5763-1050A>G variant in ATM is an intronic variant which results in an intronic A>G substitution before coding exon 38 activating a cryptic splice site leading to alternative splicing. The variant has been observed to cause an insertion of 137 nucleotides of intronic sequence at position 5762 and a premature stop codon at position 1930. Some normal splicing has been reported in patients with ATM c.5763-1050A>G, thus, the splice effect is incomplete (PMIDs 8755918, 10330348, 11382771, 15174027, Ambry internal data). This variant has been detected in many individuals with Ataxia-Telangiectasia, some of whom were described as having a mild presentation and/or later age of onset (PMIDs 8755918, 26896183). The variant has also been reported to segregate with Ataxia-Telangiectasia in 6 affected family members from 3 families (PMIDs 8755918, 15174027). The variant has a minor allele frequency in gnomAD v2.1.1 of 0.00003 (PM2_Supporting, BS1, and BA1 are not met). ATM c.5763-1050A>G has been reported as a founder variant in the British Isles (PMID 9463314). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant ATM-related cancer predisposition and autosomal recessive Ataxia-Telangiectasia based on the ACMG/AMP criteria applied, as specified by the HBOP VCEP. (PVS1_Strong (RNA), PM3_Very Strong, PP1_Strong)

Met criteria codes

PVS1_Strong	 	Near complete splicing effect, PVS1 strength reduced by one level to PVS1_RNA_strong. Approved by biocurator group based on publications below as well as Ambry internal data: observed r.5762_5763ins5762+985_5763-1055 p.P1922LFS*9 with a PSI generally around 20% (n >50 HET carriers). This splicing event is completely absent from Ambry non-carrier controls (n =373).
PP1_Strong	 	6 total affected segregations from 2 publications below. Per guidance from hearing loss VCEP (PMID: 30311386, table 4b), 6 affected segregations and 0 unaffected segregations results in a LOD score of 3.61 which is above the threshold of PP1_Strong (LOD 1.5).
PM3_Very Strong	 	Reported in several patients with AT diagnosis (11 points in total from publications below). 2 additional patients reported by Teraoka 1999 (PMID: 10330348) not counted as points already meets PM3_very strong.

Not Met criteria codes

PP3	 	No data available for splice prediction
------------	---	---

PM2



Reported as a founder variant in the British Isles. Highest subpopulation frequency is 0.00008 which is above the threshold of 0.001%.

Curation History [↗](#)

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.